- Home
- NEUP vs CARM Comparison
NEUP vs CARM Comparison
Compare NEUP & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEUP
- CARM
- Stock Information
- Founded
- NEUP 1996
- CARM 2016
- Country
- NEUP United States
- CARM United States
- Employees
- NEUP N/A
- CARM N/A
- Industry
- NEUP
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- NEUP
- CARM Health Care
- Exchange
- NEUP Nasdaq
- CARM Nasdaq
- Market Cap
- NEUP 12.7M
- CARM 12.1M
- IPO Year
- NEUP N/A
- CARM N/A
- Fundamental
- Price
- NEUP $17.24
- CARM $0.16
- Analyst Decision
- NEUP Strong Buy
- CARM Hold
- Analyst Count
- NEUP 2
- CARM 5
- Target Price
- NEUP $28.00
- CARM $0.90
- AVG Volume (30 Days)
- NEUP 95.7K
- CARM 2.1M
- Earning Date
- NEUP 11-15-2025
- CARM 11-06-2025
- Dividend Yield
- NEUP N/A
- CARM N/A
- EPS Growth
- NEUP N/A
- CARM N/A
- EPS
- NEUP N/A
- CARM N/A
- Revenue
- NEUP $15,649,448.00
- CARM $10,767,000.00
- Revenue This Year
- NEUP N/A
- CARM N/A
- Revenue Next Year
- NEUP N/A
- CARM N/A
- P/E Ratio
- NEUP N/A
- CARM N/A
- Revenue Growth
- NEUP N/A
- CARM N/A
- 52 Week Low
- NEUP $2.90
- CARM $0.14
- 52 Week High
- NEUP $126.00
- CARM $1.27
- Technical
- Relative Strength Index (RSI)
- NEUP 60.56
- CARM 29.49
- Support Level
- NEUP $14.64
- CARM $0.24
- Resistance Level
- NEUP $19.21
- CARM $0.29
- Average True Range (ATR)
- NEUP 2.14
- CARM 0.03
- MACD
- NEUP -0.03
- CARM -0.01
- Stochastic Oscillator
- NEUP 59.46
- CARM 5.24
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.